A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a ...

S&P 500, Eli Lilly and Company, Novo Nordisk A/S Class B, Novo Nordisk A/S. Read 's Market Analysis on Investing.com ...

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

Obesity — like most other medical conditions — requires an “arsenal” of treatments, rather than a one-size-fits-all approach.

Here's what the new study can tell us. A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head ...